"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to CNTA. [ FAQ on what and how to ask] For non-CNTA questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Mario Alberto Accardi Ph.D.
Headquarter: 1 Ashley Road, 3rd Floor, Altrincham, United Kingdom, WA14 2DT
Industry: Biotechnology, Investment Track: Immunology & infectious diseases, Employees: 114
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
My Watchlist
